GlassScriptPhysician profile
Michael Joseph Mccann
NPI 1437859923
$1,325.57
in general payments reported to CMS, 2019-2025
18 companies · $655 in 2025
The $655 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $340 · 2024: $331 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.59 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $268.89 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $181.91 | 2023-2024 | Mounjaro, Emgality, Reyvow |
| Abbvie INC. | $147.93 | 2023-2025 | |
| Ucb, INC. | $109.29 | 2025 | Bimzelx |
| Genzyme Corporation | $88.20 | 2025 | |
| Amgen INC. | $81.57 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $65.65 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $60.07 | 2025 | |
| Currax Pharmaceuticals LLC | $50.98 | 2023 | Contrave, Onzetra Xsail |
| Novartis Pharmaceuticals Corporation | $46.74 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $38.74 | 2023-2024 | Breztri, Airsupra |
| Botanix Sb INC | $35.92 | 2025 | Sofdra |
| Novo Nordisk INC | $32.81 | 2023 | Rybelsus, Ozempic |
| Medtronic, INC. | $30.03 | 2023 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $27.45 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $20.74 | 2024 | Zoryve |
| Scilex Pharmaceuticals INC. | $19.87 | 2023 | Ztlido |
| Pfizer INC. | $18.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.